Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.
The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.
Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.
Maze Therapeutics director Charles J. Homcy was granted a stock option to buy 18,000 shares of Maze Therapeutics common stock at an exercise price of $23.67 per share. The option is reported as a direct holding and covers 18,000 underlying shares with an exercise/expiration reference shown as 09/21/2035. The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to the holder’s continued service.
The grant increases the reporting person’s beneficial ownership by 18,000 shares on the reported transaction date of September 22, 2025. No cash exercise is indicated in the filing and the option is described as a right to buy common stock under standard vesting conditions tied to continued service.
Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share. The option was granted on 09/22/2025, is exercisable beginning 09/21/2025, and expires 09/21/2035. The award vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.
Maze Therapeutics director Nancy C. Andrews was granted a stock option on 09/22/2025 to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) common stock at an exercise price of $23.67 per share. The option award appears in a Form 4 filed on 09/24/2025 and is reported as a direct beneficial holding of 18,000 underlying shares after the transaction. The disclosure states the option will vest in nine equal monthly tranches (1/9 each month) with the first tranche vesting on October 1, 2025, subject to continued service. The instrument lists a date of exercisability/expiration of 09/21/2035 and zero listed cash paid on exercise in the table.
Maze Therapeutics director Richard H. Scheller reported a sale of company stock on September 15, 2025. The filing shows 20,744 shares of Maze common stock were disposed of in multiple transactions at a weighted average price of $22.3696 per share, with individual trade prices ranging from $22.14 to $22.585. After the reported sale the reporting person beneficially owned 0 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on September 16, 2025. The filer is identified as a director of Maze Therapeutics and the transaction is recorded as a non-derivative sale of common stock.
Maze Therapeutics reported a private placement of pre-funded warrants to raise capital and provided related registration rights and disclosures. The company sold pre-funded warrants to purchase up to 5,231,090 shares of common stock at a purchase price of $16.249 per pre-funded warrant, with each warrant exercisable for $0.001 per share and not expiring. The company agreed to file a registration statement for resale of the shares within 60 days of closing and to use reasonable best efforts to have it declared effective within 75 days of initial filing. The filing states the securities were sold without registration and only to accredited investors for investment purposes. Exhibits include forms of the warrant, purchase agreement and registration rights agreement, plus press releases announcing the private placement and MZE782 data dated September 11, 2025. The filing also contains standard forward-looking statement language identifying programs MZE829 and MZE782 and listing development, regulatory, funding and macroeconomic risks.
Tahir Misbah, Chief Financial Officer of Maze Therapeutics, Inc. (MAZE), was granted a stock option for 325,000 shares with an exercise price of $15.32. The Form 4 reports the option award dated 09/02/2025 and shows 325,000 shares beneficially owned following the transaction as a direct holding. The option includes a vesting schedule: 1/4 of the award vests on September 2, 2026, then 1/48th of the total award vests monthly thereafter, subject to continued service. The filing is signed by an attorney-in-fact on behalf of the reporting person and reports the transaction under Section 16.